Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Peginterferon Alfa-2a and Ribavirin Combination Therapy in Patients With HBeAg-negative Chronic HBV Infection (PARC Study)

NCT00114361 is registered in ClinicalTrials.gov with Foundation for Liver Research as lead sponsor.

NCT NCT00114361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00114361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Peginterferon Alfa-2a and Ribavirin Combination Therapy in Patients With HBeAg-negative Chronic HBV Infection (PARC Study)
Lead sponsor
Foundation for Liver Research
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2005
Completion date
April 30, 2010
Enrollment
138 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b